Search Result

Results for "

ROCK?Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (5) Calcium Channel (5) HIV (3) Myosin (3) PKA (8) PKC (8) ROCK (45)
By Research Areas:	Cancer (23) Cardiovascular Disease (11) Inflammation/Immunology (8) Metabolic Disease (3) Neurological Disease (6)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119937

ROCK inhibitor-2 2 Publications Verification	ROCK	Cardiovascular Disease Inflammation/Immunology
ROCK inhibitor-2 is a selective dual *ROCK1* and *ROCK2* inhibitor with IC₅₀s of 17 nM and 2 nM, respectively .

HY-101244

ZINC00881524

ROCK Cancer

ZINC00881524 is a ROCK inhibitor.
HY-10069

Y-33075 dihydrochloride

10+ Cited Publications

ROCK Cancer

Y-33075 dihydrochloride is a selective ROCK inhibitor with an IC₅₀ of 3.6 nM.

ZINC00881524	ROCK	Cancer
ZINC00881524 is a *ROCK* inhibitor.

Y-33075 dihydrochloride 10+ Cited Publications	ROCK	Cancer
Y-33075 dihydrochloride is a selective *ROCK* inhibitor with an IC₅₀ of 3.6 nM.

HY-10068

Y-33075 hydrochloride Y-39983	ROCK	Neurological Disease
Y-33075 hydrochloride (Y-39983) is a selective *ROCK* inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC₅₀ of 3.6 nM.

HY-116238

ROCK-IN-D2

ROCK Others

ROCK-IN-D2 is a potent and selective ROCK inhibitor .
HY-126913

Rhodblock 6

ROCK Cancer

Rhodblock 6 is a Rho kinase (ROCK) inhibitor that inhibits phospho-MRLC (myosin regulatory light chain) localization .

ROCK-IN-D2	ROCK	Others
ROCK-IN-D2 is a potent and selective *ROCK* inhibitor .

Rhodblock 6	ROCK	Cancer
Rhodblock 6 is a Rho kinase (ROCK) inhibitor that inhibits phospho-MRLC (myosin regulatory light chain) localization .

HY-13257

Thiazovivin 4 Publications Verification	ROCK	Cancer
Thiazovivin is a potent *ROCK* inhibitor, which can protect human embryonic stem cells. Thiazovivin improves the efficiency of iPSC generation.

HY-15720A

H-1152 dihydrochloride 1 Publications Verification	ROCK	Neurological Disease
H-1152 dihydrochloride is a membrane-permeable and selective *ROCK* inhibitor, with a K_i value of 1.6 nM, and an IC₅₀ value of 12 nM for *ROCK2*.

HY-13911

Hydroxyfasudil 3 Publications Verification HA-1100	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
Hydroxyfasudil is a *ROCK* inhibitor, with IC₅₀s of 0.73 and 0.72 μM for *ROCK1* and *ROCK2*, respectively.

HY-13911A

Hydroxyfasudil hydrochloride 3 Publications Verification HA-1100 hydrochloride; HA 1100 hydrochloride; HA1100 hydrochloride	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
Hydroxyfasudil hydrochloride is a *ROCK* inhibitor, with IC₅₀s of 0.73 and 0.72 μM for *ROCK1* and *ROCK2*, respectively.

HY-15720

H-1152 1 Publications Verification	ROCK	Neurological Disease
H-1152 is a membrane-permeable and selective *ROCK* inhibitor, with a K_i value of 1.6 nM, and an IC₅₀ value of 12 nM for *ROCK2*.

HY-10067

Y-33075

10+ Cited Publications

Y-39983 free base
ROCK Cancer

Y-33075 is a selective ROCK inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC₅₀ of 3.6 nM.

Y-33075 10+ Cited Publications Y-39983 free base	ROCK	Cancer
Y-33075 is a selective *ROCK* inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC₅₀ of 3.6 nM.

HY-113641

ROCK-IN-32	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
ROCK-IN-32 is a *ROCK* inhibitor, with an IC₅₀ value of 11 nM for *ROCK2. ROCK*-IN-32 can be used in research of cardiovascular disease, cancer and inflammation .

HY-15687

SAR407899 hydrochloride 2 Publications Verification	ROCK	Metabolic Disease
SAR407899 hydrochloride is a selective, potent and ATP-competitive *ROCK* inhibitor, with an IC₅₀ of 135 nM for *ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2*, respectively.

HY-108518

SB-772077B dihydrochloride	ROCK	Cardiovascular Disease
SB-772077B dihydrochloride is an aminofurazan-based Rho kinase (ROCK) inhibitor with IC₅₀s of 5.6 nM and 6 nM toward ROCK1 and ROCK2, respevtively .

HY-13257G

Thiazovivin	ROCK	Cancer
Thiazovivin (GMP) is Thiazovivin (HY-13257) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Thiazovivin is a potent *ROCK* inhibitor .

HY-10319

BAY-549 2 Publications Verification ROCK-IN-2; Azaindole 1; TC-S 7001	ROCK	Cardiovascular Disease
BAY-549 (Azaindole 1) is an orally active and ATP-competitive *ROCK* inhibitor with IC₅₀s of 0.6 and 1.1 nM for human *ROCK-1* and *ROCK-2*, respectively .

HY-15556

GSK269962A 2 Publications Verification GSK 269962	ROCK	Cardiovascular Disease Inflammation/Immunology
GSK269962A (GSK 269962) is a potent *ROCK* inhibitor with IC₅₀s of 1.6 and 4 nM for recombinant human *ROCK1* and *ROCK2* respectively. GSK269962A has anti-inflammatory and vasodilatory activities .

HY-100270

Rho-Kinase-IN-1	ROCK	Cancer
Rho-Kinase-IN-1 is a Rho kinase (ROCK) inhibitor (K_i values of 30.5 and 3.9 nM for ROCK1 and ROCK2, respectively) extracted from US20090325960A1, compound 1.008 .

HY-15556A

GSK269962A hydrochloride GSK 269962 hydrochloride	ROCK	Cardiovascular Disease Inflammation/Immunology
GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent *ROCK* inhibitor with IC₅₀s of 1.6 and 4 nM for recombinant human *ROCK1* and *ROCK2* respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities .

HY-15687A

SAR407899 2 Publications Verification	ROCK	Metabolic Disease
SAR407899 is a selective, potent and ATP-competitive *ROCK* inhibitor, with an IC₅₀ of 135 nM for *ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2*, respectively. SAR407899 shows stable inhibition of migrasome formation.

HY-110339

RKI-1447 dihydrochloride 2 Publications Verification	ROCK Apoptosis	Cancer
RKI 1447 dihydrochloride is a potent and selective *ROCK* inhibitor with IC₅₀s of 14.5 and 6.2 nM for *ROCK1* and *ROCK2, respectively . RKI 1447 dihydrochloride suppresses colorectal carcinoma cell growth and promotes apoptosis* .

HY-110335

OXA-06 hydrochloride	ROCK	Cancer
OXA-06 hydrochloride is an ATP-competitive *ROCK* inhibitor that blocks anchorage-dependent growth and invasion of non-small cell lung cancer cell lines. OXA-06 hydrochloride inhibits cofilin phosphorylation but does not stimulate apoptosis .

HY-10833

ROCK-IN-10	ROCK	Cardiovascular Disease
ROCK-IN-10 (compound 50) is a potent *ROCK* inhibitor with IC₅₀ values of 6 nM and 4 nM for ROCK1 and ROCK2, respectively. ROCK-IN-10 shows >100-fold selectivity against other kinases .

HY-156550

ROCK-IN-8	ROCK	Inflammation/Immunology
ROCK-IN-8 (Example 4) is a *ROCK* inhibitor, with an IC₅₀ value less than 100 nM. ROCK-IN-8 has anti-inflammatory activity. ROCK-IN-8 can be used for research of respiratory and gastro-intestinal diseases .

HY-112362

3-(4-Pyridyl)indole Rockout; 3-(4-Pyridinyl)-1H-indole; Rho Kinase Inhibitor III, Rockout	ROCK	Inflammation/Immunology
3-(4-Pyridyl)indole (Rockout) is a Rho-kinase (ROCK) inhibitor, with an IC₅₀ of 25 μM. 3-(4-Pyridyl)indole can inhibit blebbing and cause dissolution of actin stress fibers in a wound healing assay .

HY-107209

RKI-1313	ROCK	Cancer
RKI-1313 is a *ROCK* inhibitor with IC₅₀s of 34, 8 µM for ROCK 1 and ROCK 2, respectively. RKI-1313 shows little effect on the phosphorylation levels of ROCK substrates, migration, invasion or anchorage-independent growth .

HY-126275

HSD1590	ROCK	Cancer
HSD1590 is potent *ROCK* inhibitor, with IC₅₀s of 1.22 and 0.51 nM for ROCK1 and ROCK2, respectively. HSD1590 exhibits single digit nanomolar binding to ROCK (K_ds<2 nM). HSD1590 displays low cytotoxicity .

HY-151189

ROCK-IN-4	ROCK	Others
ROCK-IN-4 is a potent *ROCK* inhibitor maintaining NO releasing ability. ROCK-IN-4 reversibly depolymerizes F-actin, and suppresses mitochondrial respiration in human trabecular meshwork (HTM) cells. ROCK-IN-4 can be used for glaucoma or ocular hypertension research .

HY-139170

CAY10746	ROCK	Metabolic Disease
CAY10746 is a selective Rho kinase (ROCK) inhibitor. CAY10746 has inhibitory activity for ROCK I, ROCK II with IC₅₀ values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be used for the research of diabetic retinopathy (DR) .

HY-109191

Sovesudil PHP-201; AMA0076	ROCK	Others
Sovesudil (PHP-201) is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC₅₀s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil lowers intraocular pressure (IOP) without inducing hyperemia .

HY-109191A

Sovesudil hydrochloride PHP-201 hydrochloride; AMA0076 hydrochloride	ROCK	Neurological Disease
Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho kinase *(ROCK)* inhibitor with IC₅₀s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia .

HY-16758

Verosudil AR-12286	ROCK	Neurological Disease
Verosudil (AR-12286) is a potent, selective Rho-kinase (ROCK) inhibitor with K_is of 2 and 2 nM for ROCK1 and ROCK2, respectively. AR-12286 lowers intraocular pressure (IOP) primarily by increasing aqueous humour outflow through the trabecular meshwork .

HY-150640

Rho-Kinase-IN-2	ROCK	Neurological Disease
Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC₅₀=3 nM). Rho-Kinase-IN-2 can be used in Huntington’s research .

HY-156593

ROCK-IN-9	ROCK	Cancer
ROCK-IN-9 (Compound T345) is a *ROCK* inhibitor. ROCK-IN-9 shows cytotoxicity in HepG2 cell, with an IC₅₀ of 40.8 μM. ROCK-IN-9 has good pharmacokinetic properties in mice, and shows high in vivo exposure and oral bioavailability at lower doses .

HY-15392

Chroman 1 Maximum Cited Publications 18 Publications Verification	ROCK	Cardiovascular Disease
Chroman 1 is a highly potent and selective *ROCK* inhibitor. Chroman 1 is more potent against ROCK2 (IC₅₀=1 pM) than ROCK1 (IC₅₀=52 pM). Chroman 1 also has inhibitory activity against MRCK, with an IC₅₀ of 150 nM .

HY-15392A

Chroman 1 dihydrochloride Maximum Cited Publications 18 Publications Verification	ROCK	Cardiovascular Disease
Chroman 1 dihydrochloride is a highly potent and selective *ROCK* inhibitor. Chroman 1 dihydrochloride is more potent against ROCK2 (IC₅₀=1 pM) than ROCK1 (IC₅₀=52 pM). Chroman 1 dihydrochloride also has inhibitory activity against MRCK, with an IC₅₀ of 150 nM .

HY-100984

HA-100 1 Publications Verification	PKA PKC Myosin ROCK	Cancer
HA-100 is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a *ROCK* inhibitor .

HY-100984A

HA-100 hydrochloride	PKA PKC Myosin ROCK	Cancer
HA-100 hydrochloride is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a *ROCK* inhibitor .

HY-12880

HA-100 dihydrochloride	Myosin PKA PKC ROCK	Cancer
HA-100 dihydrochloride is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a *ROCK* inhibitor .

HY-10341

Fasudil Hydrochloride 10+ Cited Publications HA-1077 Hydrochloride; AT-877 Hydrochloride	ROCK Calcium Channel Autophagy PKA PKC HIV	Cancer
Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil Hydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341A

Fasudil HA-1077; AT877	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341C

Fasudil dihydrochloride HA-1077 dihydrochloride; AT-877 dihydrochloride	Calcium Channel ROCK PKA PKC Autophagy HIV	Cancer
Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil dihydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341B

Fasudil hydrochloride semihydrate HA-1077 hydrochloride semihydrate; AT877 hydrochloride semihydrate	ROCK Calcium Channel Autophagy HIV PKA PKC	Cancer
Fasudil (HA-1077; AT877) hydrochloride semihydrate is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil hydrochloride semihydrate is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-100035

PT-262
PT-262 is a potent *ROCK* inhibitor with an IC₅₀ value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity .

HY-10341D

Fasudil mesylate HA-1077 mesylate; AT-877 mesylate	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) mesylate is a nonspecific and orally active *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil mesylate is also a potent Ca ²⁺ channel antagonist and vasodilator .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: